We serve Chemical Name:3-(4-Acetylphenoxy)propanoic acid CAS:91143-72-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(4-Acetylphenoxy)propanoic acid
CAS.NO:91143-72-5
Synonyms:3-(4-Acetylphenoxy)propanoic acid
Molecular Formula:C11H12O4
Molecular Weight:208.21100
HS Code:2918990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:63.60000
Exact Mass:208.07400
LogP:1.74270
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(4-Acetylphenoxy)propanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(4-Acetylphenoxy)propanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(4-Acetylphenoxy)propanoic acid Use and application,3-(4-Acetylphenoxy)propanoic acid technical grade,usp/ep/jp grade.
Related News: Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 2,9-dimethyl-4,7-dioxo-3,5,6,8-tetraoxa-decanedioic acid diethyl ester manufacturers The UK government has set out plans to make the UK the best destination in the world for researchers, making sure that it continues to attract the brightest and best from the UK and from overseas, cementing its status as a science superpower. 1-[4-(3-Cycloheptylamino-2-hydroxy-propoxy)-phenyl]-3-cyclohexyl-urea suppliers AstraZeneca’s deal, the largest struck last year, is all part of CEO Pascal Soriot’s mission to hit $40 billion in global sales by 2023. 14,14-dideuterio-octadec-9c-enoic acid methyl ester vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 2,9-dimethyl-4,7-dioxo-3,5,6,8-tetraoxa-decanedioic acid diethyl ester manufacturers The UK government has set out plans to make the UK the best destination in the world for researchers, making sure that it continues to attract the brightest and best from the UK and from overseas, cementing its status as a science superpower. 1-[4-(3-Cycloheptylamino-2-hydroxy-propoxy)-phenyl]-3-cyclohexyl-urea suppliers AstraZeneca’s deal, the largest struck last year, is all part of CEO Pascal Soriot’s mission to hit $40 billion in global sales by 2023. 14,14-dideuterio-octadec-9c-enoic acid methyl ester vendor & factory.
